Skip to main content
. 2019 Sep 6;8(9):1404. doi: 10.3390/jcm8091404

Table 1.

Demographic characteristics, comorbid conditions and prognostic scales in community-acquired pneumonia (CAP) according to organ failure.

Organ Dysfunction
n
52 (55.3)
Yes
42 (44.7)
p-Value
Demographics
Age (years) 60 (42–69) 70 (56–78) * 0.002
Gender (male) 32 (61.5) 24 (57.1) 0.666
Pneumococcal vaccination 1 (1.9) 3 (7.1) 0.213
Influenza vaccination 14 (26.9) 16 (38.1) 0.248
Current smoker 10 (19.2) 10 (23.8) 0.081
Alcohol abuse (>80 g/day) 2 (3.8) 2 (4.8) 0.179
Prior antibiotic treatment (last month) 22 (42.3) 14 (33.3) 0.374
Comorbid condition
Diabetes mellitus 3 (5.8) 9 (21.4) * 0.024
Chronic liver disease 0 (0) 1 (2.4) 0.263
Heart disease 13 (25) 15 (35.7) 0.259
Renal disease 2 (3.8) 5 (11.9) 0.139
Neurological disease 2 (3.8) 5 (11.9) 0.139
COPD 3 (5.8) 15 (35.7) * <0.001
Charlson comorbidity index 0 (0–1) 1 (1–2) * <0.001
Prognostic scales
PSI (IV–V) 6 (11.5) 18 (42.9) * 0.001
CURB65 1 (0–1) 2 (1–2) * <0.001
Analytical parameters on admission
C-reactive protein (mg/dL) 15.07 (6.32–25.32) 23.64 (9.65–33.44) * 0.046
Leukocytes (cell/mm3) 12955 (8470–16800) 15115 (10330–19710) 0.090
Neutrophils (%) 81.3 (75.7–84.8) 87 (81.6–90.3) * 0.001
Neutrophils (cell/mm3) 10692 (6481–14203) 13561 (7735–17597) * 0.043
Lymphocytes (%) 8.8 (6.6–12.8) 6.8 (4.2–8.9) * 0.005
Lymphocytes (cell/mm3) 1061 (795–1518) 854 (589–1292) 0.057
Outcomes
Length of stay (days) 6 (4–8) 7 (5–10) 0.018
Clinical stability achieved 52 (100) 38 (90.5) * 0.023
Time to clinical stability (days) 2 (1–3) 5 (3–7) * <0.001
Treatment failure 2 (3.8) 6 (14.3) 0.071
30-days mortality 0 (0) 2 (4.8) 0.112

Data presented as n (%) or median (interquartile range); COPD: chronic obstructive pulmonary disease; CURB65: confusion, urea, respiratory rate, blood pressure, 65 years; PSI: pneumonia severity index. * p < 0.05.